The Scalability Challenge in MSC Therapies
John Yoshi Shyu on why mesenchymal stem cell programs stall – and how early manufacturing decisions can determine clinical and commercial success
Clinical Scorecard: The Scalability Challenge in MSC Therapies
At a Glance
| Category | Detail |
|---|
| Condition | Mesenchymal Stem Cell (MSC) Therapy |
| Key Mechanisms | Manufacturing scalability, donor-to-donor variability, early-stage trial design |
| Target Population | Patients requiring MSC therapies |
| Care Setting | Clinical and commercial manufacturing environments |
Key Highlights
- Donor-to-donor variability complicates efficacy demonstration.
- Cost of goods (COGS) understanding is crucial for sustainable processes.
- Regulatory expectations shift from flexibility to predictability in late-stage trials.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients undergoing MSC therapies in clinical trials and commercial settings.
Focus on standardized, closed, and automated manufacturing systems.
Clinical Best Practices
Related Resources & Content
